

**AMENDMENTS TO THE SPECIFICATION**

**Please replace the paragraph beginning on page 1, line 4 of the specification with the following amended paragraph:**

This application is a divisional of U.S. patent application Serial No. 09/766,678, filed January 23, 2001, now U.S. Patent No. 6,872,699, which is a continuation of U.S. patent application Serial No. 08/965,598 filed, November 6, 1997, now abandoned, which is a continuation of U.S. patent application Serial No. 08/193,829, filed February 9, 1994, now U.S. Patent No. 6,177,401, which is a continuation-in-part of U.S. patent application Serial No. 08/038,596, filed March 26, 1993, now abandoned, which is a continuation-in-part of U.S. patent application Serial No. 07/975,750, filed November 13, 1992, now abandoned, all of which are incorporated by reference herein in their ~~entirety~~ entireties.

**Please replace the Abstract of the Disclosure with the following new Abstract:**

The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.

**Please replace the paragraph beginning on page 8, line 1 of the application with the following new paragraph:**

**FIG. 11-FIGS. 11-1, 11-2, 11-3 and 11-4. Nucleotide Sequence of Murine Flk-1 Nucleotide sequence [SEQ ID NO: 1] and amino acid sequence [SEQ ID NO: 2] Flk-1.**